HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): G. Chad Hughes Mani A. Daneshmand Walter G. Wolfe Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hughes, G. C. Articles by McCann, R. L. Search for Related Content PubMed PubMed Citation Articles by Hughes, G. C. Articles by McCann, R. L. Related Collections Great vessels

---

Original Articles: Adult Cardiac

"Real World" Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval

^a Department of Surgery, Duke University Medical Center, Durham, North Carolina
^b Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina
^c Department of Medicine, Duke University Medical Center, Durham, North Carolina

Accepted for publication July 23, 2008.

^_* Address correspondence to Dr Hughes, Duke University Medical Center, Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Box 3051, Durham, NC 27710 (Email: gchad.hughes{at}duke.edu).

Presented at the Fifty-fourth Annual Meeting of the Southern Thoracic Surgical Association, Bonita Springs, FL, Nov 7–10, 2007.

Background: The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize "real world" use and results outside the clinical trial setting.

Methods: Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A "hybrid" approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone.

Results: Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%).

Conclusions: "Real world" utilization of the TAG device includes high rates of off-label use (nearly 50%) and "hybrid" techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.

This article has been cited by other articles:

				G. C. Hughes, C. F. Sulzer, R. L. McCann, and M. Swaminathan Endovascular Approaches to Complex Thoracic Aortic Disease Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2008; 12(4): 298 - 319. [Abstract] [PDF]